SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily...
Related Questions
What are the potential long‑term implications for the stock’s valuation and inclusion in index funds?
Is there any anticipated change in the company’s dividend policy or share buy‑back program due to the delisting?
What is the expected short‑term impact of the voluntary delisting on ONCY’s share liquidity and price volatility?
Will the removal from the Toronto Stock Exchange affect cross‑border trading volumes or the participation of Canadian investors?
Does the delisting signal broader strategic shifts that could impact the company’s pipeline or partnership plans?
Will the delisting affect the company’s ability to raise capital in the near future?
How does the delisting compare to similar actions taken by peer biotech companies, and what were the market reactions in those cases?
How might the delisting influence institutional and retail investor demand for the stock?
Are there any regulatory or compliance costs associated with the delisting that could affect earnings?
Could the delisting trigger a re‑rating or coverage change by analysts covering ONCY?